Search
Search
About
Log in
Join
Experiences with
Vemurafenib
Posts
Communities
1 public post
Filter results
BRAF/MEK combo raises risk of cardiovascular adverse events compared to BRAF monotherapy only
Three BRAF inhibitors -- dabrafenib,
vemurafenib
, and encorafenib -- are now approved by the FDA and the European Medicines Agency, as are three MEK inhibitors -- trametinib, cobimetinib, and binimetinib.
Three BRAF inhibitors -- dabrafenib,
vemurafenib
, and encorafenib -- are now approved by the FDA and the European Medicines Agency, as are three MEK inhibitors -- trametinib, cobimetinib, and binimetinib.
missyrand
Ambassador
in
Melanoma Caregivers
5 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Filter results
Clear filters
Posted in
All communities
Melanoma Caregivers
1 result
Sort by
Most Relevant
Newest